Selected research
Market Outlook & Growth Opportunities
Global Oligonucleotide Therapy-based Drug Market Outlook and Growth Opportunities 2026
Market perspective
The global Oligonucleotide Therapy-based Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Oligonucleotide Therapy-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Oligonucleotide Therapy-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Oligonucleotide Therapy-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Oligonucleotide Therapy-based Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Oligonucleotide Therapy-based Drug market include Sobi, Novartis, Pfizer, Biogen, Sylentis, Silence Therapeutics, Secarna, Sarepta Therapeutics and Regulus Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Oligonucleotide Therapy-based Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Oligonucleotide Therapy-based Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Oligonucleotide Therapy-based Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oligonucleotide Therapy-based Drug market.
Oligonucleotide Therapy-based Drug Segment by Company
Sobi
Novartis
Pfizer
Biogen
Sylentis
Silence Therapeutics
Secarna
Sarepta Therapeutics
Regulus Therapeutics
ProQR
Nippon Shinyaku
Moderna Therapeutics
MiNA Therapeutics
Jazz Pharmaceuticals
Ionis Pharmaceuticals
Dicerna
CureVac
BioNTech
Arrowhead
Alnylam
Oligonucleotide Therapy-based Drug Segment by Type
mRNA
siRNA
Antisense Oligonucleotides (ASO)
Oligonucleotide Therapy-based Drug Segment by Application
hATTR
Neuromuscular Diseases
COVID-19
Other
Oligonucleotide Therapy-based Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Oligonucleotide Therapy-based Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Oligonucleotide Therapy-based Drug key companies, revenue, market share, and recent developments.
3. To split the Oligonucleotide Therapy-based Drug breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Oligonucleotide Therapy-based Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Oligonucleotide Therapy-based Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Oligonucleotide Therapy-based Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Therapy-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Therapy-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Therapy-based Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oligonucleotide Therapy-based Drug industry.
Chapter 3: Detailed analysis of Oligonucleotide Therapy-based Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Oligonucleotide Therapy-based Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Oligonucleotide Therapy-based Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Oligonucleotide Therapy-based Drug Industry Trends
Table 2. Oligonucleotide Therapy-based Drug Industry Drivers
Table 3. Oligonucleotide Therapy-based Drug Industry Opportunities and Challenges
Table 4. Oligonucleotide Therapy-based Drug Industry Restraints
Table 5. Global Oligonucleotide Therapy-based Drug Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Oligonucleotide Therapy-based Drug Revenue Share by Company (2021-2026)
Table 7. Global Oligonucleotide Therapy-based Drug Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Oligonucleotide Therapy-based Drug Key Company Manufacturing Base & Headquarters
Table 9. Global Oligonucleotide Therapy-based Drug Company, Product Type & Application
Table 10. Global Oligonucleotide Therapy-based Drug Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Oligonucleotide Therapy-based Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of mRNA
Table 15. Significant Companies of siRNA
Table 16. Significant Companies of Antisense Oligonucleotides (ASO)
Table 17. Global Oligonucleotide Therapy-based Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 18. Global Oligonucleotide Therapy-based Drug Sales Value by Type (2021-2026) & (US$ Million)
Table 19. Global Oligonucleotide Therapy-based Drug Sales Value by Type (2027-2032) & (US$ Million)
Table 20. Global Oligonucleotide Therapy-based Drug Sales Value Share by Type (2021-2026)
Table 21. Global Oligonucleotide Therapy-based Drug Sales Value Share by Type (2027-2032)
Table 22. Significant Companies of hATTR
Table 23. Significant Companies of Neuromuscular Diseases
Table 24. Significant Companies of COVID-19
Table 25. Significant Companies of Other
Table 26. Global Oligonucleotide Therapy-based Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 27. Global Oligonucleotide Therapy-based Drug Sales Value by Application (2021-2026) & (US$ Million)
Table 28. Global Oligonucleotide Therapy-based Drug Sales Value by Application (2027-2032) & (US$ Million)
Table 29. Global Oligonucleotide Therapy-based Drug Sales Value Share by Application (2021-2026)
Table 30. Global Oligonucleotide Therapy-based Drug Sales Value Share by Application (2027-2032)
Table 31. Global Oligonucleotide Therapy-based Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 32. Global Oligonucleotide Therapy-based Drug Sales Value by Region (2021-2026) & (US$ Million)
Table 33. Global Oligonucleotide Therapy-based Drug Sales Value Share by Region (2021-2026)
Table 34. Global Oligonucleotide Therapy-based Drug Sales Value by Region (2027-2032) & (US$ Million)
Table 35. Global Oligonucleotide Therapy-based Drug Sales Value Share by Region (2027-2032)
Table 36. Global Oligonucleotide Therapy-based Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Global Oligonucleotide Therapy-based Drug Sales Value by Country (2021-2026) & (US$ Million)
Table 38. Global Oligonucleotide Therapy-based Drug Sales Value Market Share by Country (2021-2026)
Table 39. Global Oligonucleotide Therapy-based Drug Sales Value by Country (2027-2032) & (US$ Million)
Table 40. Global Oligonucleotide Therapy-based Drug Sales Value Market Share by Country (2027-2032)
Table 41. Sobi Company Information
Table 42. Sobi Business Overview
Table 43. Sobi Oligonucleotide Therapy-based Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Sobi Oligonucleotide Therapy-based Drug Product Portfolio
Table 45. Sobi Recent Development
Table 46. Novartis Company Information
Table 47. Novartis Business Overview
Table 48. Novartis Oligonucleotide Therapy-based Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 49. Novartis Oligonucleotide Therapy-based Drug Product Portfolio
Table 50. Novartis Recent Development
Table 51. Pfizer Company Information
Table 52. Pfizer Business Overview
Table 53. Pfizer Oligonucleotide Therapy-based Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 54. Pfizer Oligonucleotide Therapy-based Drug Product Portfolio
Table 55. Pfizer Recent Development
Table 56. Biogen Company Information
Table 57. Biogen Business Overview
Table 58. Biogen Oligonucleotide Therapy-based Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 59. Biogen Oligonucleotide Therapy-based Drug Product Portfolio
Table 60. Biogen Recent Development
Table 61. Sylentis Company Information
Table 62. Sylentis Business Overview
Table 63. Sylentis Oligonucleotide Therapy-based Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 64. Sylentis Oligonucleotide Therapy-based Drug Product Portfolio
Table 65. Sylentis Recent Development
Table 66. Silence Therapeutics Company Information
Table 67. Silence Therapeutics Business Overview
Table 68. Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 69. Silence Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
Table 70. Silence Therapeutics Recent Development
Table 71. Secarna Company Information
Table 72. Secarna Business Overview
Table 73. Secarna Oligonucleotide Therapy-based Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 74. Secarna Oligonucleotide Therapy-based Drug Product Portfolio
Table 75. Secarna Recent Development
Table 76. Sarepta Therapeutics Company Information
Table 77. Sarepta Therapeutics Business Overview
Table 78. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 79. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
Table 80. Sarepta Therapeutics Recent Development
Table 81. Regulus Therapeutics Company Information
Table 82. Regulus Therapeutics Business Overview
Table 83. Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 84. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
Table 85. Regulus Therapeutics Recent Development
Table 86. ProQR Company Information
Table 87. ProQR Business Overview
Table 88. ProQR Oligonucleotide Therapy-based Drug Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. ProQR Oligonucleotide Therapy-based Drug Product Portfolio
Table 90. ProQR Recent Development
Table 91. Nippon Shinyaku Company Information
Table 92. Nippon Shinyaku Business Overview
Table 93. Nippon Shinyaku Oligonucleotide Therapy-based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 94. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Portfolio
Table 95. Nippon Shinyaku Recent Development
Table 96. Moderna Therapeutics Company Information
Table 97. Moderna Therapeutics Business Overview
Table 98. Moderna Therapeutics Oligonucleotide Therapy-based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 99. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
Table 100. Moderna Therapeutics Recent Development
Table 101. MiNA Therapeutics Company Information
Table 102. MiNA Therapeutics Business Overview
Table 103. MiNA Therapeutics Oligonucleotide Therapy-based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 104. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
Table 105. MiNA Therapeutics Recent Development
Table 106. Jazz Pharmaceuticals Company Information
Table 107. Jazz Pharmaceuticals Business Overview
Table 108. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 109. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
Table 110. Jazz Pharmaceuticals Recent Development
Table 111. Ionis Pharmaceuticals Company Information
Table 112. Ionis Pharmaceuticals Business Overview
Table 113. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 114. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
Table 115. Ionis Pharmaceuticals Recent Development
Table 116. Dicerna Company Information
Table 117. Dicerna Business Overview
Table 118. Dicerna Oligonucleotide Therapy-based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 119. Dicerna Oligonucleotide Therapy-based Drug Product Portfolio
Table 120. Dicerna Recent Development
Table 121. CureVac Company Information
Table 122. CureVac Business Overview
Table 123. CureVac Oligonucleotide Therapy-based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 124. CureVac Oligonucleotide Therapy-based Drug Product Portfolio
Table 125. CureVac Recent Development
Table 126. BioNTech Company Information
Table 127. BioNTech Business Overview
Table 128. BioNTech Oligonucleotide Therapy-based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 129. BioNTech Oligonucleotide Therapy-based Drug Product Portfolio
Table 130. BioNTech Recent Development
Table 131. Arrowhead Company Information
Table 132. Arrowhead Business Overview
Table 133. Arrowhead Oligonucleotide Therapy-based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 134. Arrowhead Oligonucleotide Therapy-based Drug Product Portfolio
Table 135. Arrowhead Recent Development
Table 136. Alnylam Company Information
Table 137. Alnylam Business Overview
Table 138. Alnylam Oligonucleotide Therapy-based Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026)
Table 139. Alnylam Oligonucleotide Therapy-based Drug Product Portfolio
Table 140. Alnylam Recent Development
Table 141. Research Programs/Design for This Report
Table 142. Authors List of This Report
Table 143. Secondary Sources
Table 144. Primary Sources
List of Figures
Figure 1. Oligonucleotide Therapy-based Drug Product Image
Figure 2. Global Oligonucleotide Therapy-based Drug Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million)
Figure 4. Global Oligonucleotide Therapy-based Drug Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. mRNA Image
Figure 8. siRNA Image
Figure 9. Antisense Oligonucleotides (ASO) Image
Figure 10. Global Oligonucleotide Therapy-based Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 11. Global Oligonucleotide Therapy-based Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 12. Global Oligonucleotide Therapy-based Drug Sales Value Share by Type (2021-2032)
Figure 13. hATTR Image
Figure 14. Neuromuscular Diseases Image
Figure 15. COVID-19 Image
Figure 16. Other Image
Figure 17. Global Oligonucleotide Therapy-based Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 18. Global Oligonucleotide Therapy-based Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 19. Global Oligonucleotide Therapy-based Drug Sales Value Share by Application (2021-2032)
Figure 20. Global Oligonucleotide Therapy-based Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 21. Global Oligonucleotide Therapy-based Drug Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 22. North America Oligonucleotide Therapy-based Drug Sales Value (2021-2032) & (US$ Million)
Figure 23. North America Oligonucleotide Therapy-based Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 24. Europe Oligonucleotide Therapy-based Drug Sales Value (2021-2032) & (US$ Million)
Figure 25. Europe Oligonucleotide Therapy-based Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 26. Asia-Pacific Oligonucleotide Therapy-based Drug Sales Value (2021-2032) & (US$ Million)
Figure 27. Asia-Pacific Oligonucleotide Therapy-based Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 28. South America Oligonucleotide Therapy-based Drug Sales Value (2021-2032) & (US$ Million)
Figure 29. South America Oligonucleotide Therapy-based Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 30. Middle East & Africa Oligonucleotide Therapy-based Drug Sales Value (2021-2032) & (US$ Million)
Figure 31. Middle East & Africa Oligonucleotide Therapy-based Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 32. USA Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 33. USA Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 34. USA Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 35. Canada Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 36. Canada Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 37. Canada Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 38. Mexico Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 39. Mexico Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 40. Mexico Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 41. Germany Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 42. Germany Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 43. Germany Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 44. France Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 45. France Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 46. France Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 47. U.K. Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 48. U.K. Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 49. U.K. Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 50. Italy Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 51. Italy Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 52. Italy Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 53. Spain Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 54. Spain Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 55. Spain Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 56. Russia Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 57. Russia Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 58. Russia Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 59. Netherlands Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 60. Netherlands Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 61. Netherlands Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 62. Nordic Countries Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 63. Nordic Countries Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 64. Nordic Countries Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 65. China Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 66. China Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 67. China Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 68. Japan Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 69. Japan Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 70. Japan Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 71. South Korea Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 72. South Korea Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 73. South Korea Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 74. India Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 75. India Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 76. India Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 77. Australia Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 78. Australia Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 79. Australia Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 80. Southeast Asia Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 81. Southeast Asia Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 82. Southeast Asia Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 83. Brazil Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 84. Brazil Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 85. Brazil Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 86. Argentina Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 87. Argentina Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 88. Argentina Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 89. Chile Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 90. Chile Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 91. Chile Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 92. Colombia Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 93. Colombia Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 94. Colombia Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 95. Peru Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 96. Peru Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 97. Peru Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 98. Saudi Arabia Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 99. Saudi Arabia Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 100. Saudi Arabia Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 101. Israel Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 102. Israel Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 103. Israel Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 104. UAE Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 105. UAE Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 106. UAE Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 107. Turkey Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 108. Turkey Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 109. Turkey Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 110. Iran Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 111. Iran Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 112. Iran Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 113. Egypt Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 114. Egypt Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 115. Egypt Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 116. Years Considered
Figure 117. Research Process
Figure 118. Key Executives Interviewed
Scope & coverage.
Types
- mRNA
- siRNA
- Antisense Oligonucleotides (ASO)
Applications
- hATTR
- Neuromuscular Diseases
- COVID-19
- Other
Companies covered
- Sobi
- Novartis
- Pfizer
- Biogen
- Sylentis
- Silence Therapeutics
- Secarna
- Sarepta Therapeutics
- Regulus Therapeutics
- ProQR
- Nippon Shinyaku
- Moderna Therapeutics
- MiNA Therapeutics
- Jazz Pharmaceuticals
- Ionis Pharmaceuticals
- Dicerna
- CureVac
- BioNTech
- Arrowhead
- Alnylam
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Oligonucleotide Therapy-based Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Oligonucleotide Therapy-based Drug Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Oligonucleotide Therapy-based Drug Market Dynamics
- 2.1 Oligonucleotide Therapy-based Drug Industry Trends
- 2.2 Oligonucleotide Therapy-based Drug Industry Drivers
- 2.3 Oligonucleotide Therapy-based Drug Industry Opportunities and Challenges
- 2.4 Oligonucleotide Therapy-based Drug Industry Restraints
3 Oligonucleotide Therapy-based Drug Market by Company
- 3.1 Global Oligonucleotide Therapy-based Drug Company Revenue Ranking in 2025
- 3.2 Global Oligonucleotide Therapy-based Drug Revenue by Company (2021-2026)
- 3.3 Global Oligonucleotide Therapy-based Drug Company Ranking (2024-2026)
- 3.4 Global Oligonucleotide Therapy-based Drug Company Manufacturing Base and Headquarters
- 3.5 Global Oligonucleotide Therapy-based Drug Company Product Type and Application
- 3.6 Global Oligonucleotide Therapy-based Drug Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Oligonucleotide Therapy-based Drug Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Oligonucleotide Therapy-based Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Oligonucleotide Therapy-based Drug Market by Type
- 4.1 Oligonucleotide Therapy-based Drug Type Introduction
- 4.1.1 mRNA
- 4.1.2 siRNA
- 4.1.3 Antisense Oligonucleotides (ASO)
- 4.2 Global Oligonucleotide Therapy-based Drug Sales Value by Type
- 4.2.1 Global Oligonucleotide Therapy-based Drug Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Oligonucleotide Therapy-based Drug Sales Value by Type (2021-2032)
- 4.2.3 Global Oligonucleotide Therapy-based Drug Sales Value Share by Type (2021-2032)
5 Oligonucleotide Therapy-based Drug Market by Application
- 5.1 Oligonucleotide Therapy-based Drug Application Introduction
- 5.1.1 hATTR
- 5.1.2 Neuromuscular Diseases
- 5.1.3 COVID-19
- 5.1.4 Other
- 5.2 Global Oligonucleotide Therapy-based Drug Sales Value by Application
- 5.2.1 Global Oligonucleotide Therapy-based Drug Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Oligonucleotide Therapy-based Drug Sales Value by Application (2021-2032)
- 5.2.3 Global Oligonucleotide Therapy-based Drug Sales Value Share by Application (2021-2032)
6 Oligonucleotide Therapy-based Drug Regional Value Analysis
- 6.1 Global Oligonucleotide Therapy-based Drug Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Oligonucleotide Therapy-based Drug Sales Value by Region (2021-2032)
- 6.2.1 Global Oligonucleotide Therapy-based Drug Sales Value by Region: 2021-2026
- 6.2.2 Global Oligonucleotide Therapy-based Drug Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Oligonucleotide Therapy-based Drug Sales Value (2021-2032)
- 6.3.2 North America Oligonucleotide Therapy-based Drug Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Oligonucleotide Therapy-based Drug Sales Value (2021-2032)
- 6.4.2 Europe Oligonucleotide Therapy-based Drug Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Oligonucleotide Therapy-based Drug Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Oligonucleotide Therapy-based Drug Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Oligonucleotide Therapy-based Drug Sales Value (2021-2032)
- 6.6.2 South America Oligonucleotide Therapy-based Drug Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Oligonucleotide Therapy-based Drug Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Oligonucleotide Therapy-based Drug Sales Value Share by Country, 2025 VS 2032
7 Oligonucleotide Therapy-based Drug Country-level Value Analysis
- 7.1 Global Oligonucleotide Therapy-based Drug Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Oligonucleotide Therapy-based Drug Sales Value by Country (2021-2032)
- 7.2.1 Global Oligonucleotide Therapy-based Drug Sales Value by Country (2021-2026)
- 7.2.2 Global Oligonucleotide Therapy-based Drug Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.7.2 France Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.14.2 China Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.17.2 India Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Oligonucleotide Therapy-based Drug Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Oligonucleotide Therapy-based Drug Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Oligonucleotide Therapy-based Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Sobi
- 8.1.1 Sobi Company Information
- 8.1.2 Sobi Business Overview
- 8.1.3 Sobi Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.1.4 Sobi Oligonucleotide Therapy-based Drug Product Portfolio
- 8.1.5 Sobi Recent Developments
- 8.2 Novartis
- 8.2.1 Novartis Company Information
- 8.2.2 Novartis Business Overview
- 8.2.3 Novartis Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.2.4 Novartis Oligonucleotide Therapy-based Drug Product Portfolio
- 8.2.5 Novartis Recent Developments
- 8.3 Pfizer
- 8.3.1 Pfizer Company Information
- 8.3.2 Pfizer Business Overview
- 8.3.3 Pfizer Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.3.4 Pfizer Oligonucleotide Therapy-based Drug Product Portfolio
- 8.3.5 Pfizer Recent Developments
- 8.4 Biogen
- 8.4.1 Biogen Company Information
- 8.4.2 Biogen Business Overview
- 8.4.3 Biogen Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.4.4 Biogen Oligonucleotide Therapy-based Drug Product Portfolio
- 8.4.5 Biogen Recent Developments
- 8.5 Sylentis
- 8.5.1 Sylentis Company Information
- 8.5.2 Sylentis Business Overview
- 8.5.3 Sylentis Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.5.4 Sylentis Oligonucleotide Therapy-based Drug Product Portfolio
- 8.5.5 Sylentis Recent Developments
- 8.6 Silence Therapeutics
- 8.6.1 Silence Therapeutics Company Information
- 8.6.2 Silence Therapeutics Business Overview
- 8.6.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.6.4 Silence Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
- 8.6.5 Silence Therapeutics Recent Developments
- 8.7 Secarna
- 8.7.1 Secarna Company Information
- 8.7.2 Secarna Business Overview
- 8.7.3 Secarna Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.7.4 Secarna Oligonucleotide Therapy-based Drug Product Portfolio
- 8.7.5 Secarna Recent Developments
- 8.8 Sarepta Therapeutics
- 8.8.1 Sarepta Therapeutics Company Information
- 8.8.2 Sarepta Therapeutics Business Overview
- 8.8.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.8.4 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
- 8.8.5 Sarepta Therapeutics Recent Developments
- 8.9 Regulus Therapeutics
- 8.9.1 Regulus Therapeutics Company Information
- 8.9.2 Regulus Therapeutics Business Overview
- 8.9.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.9.4 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
- 8.9.5 Regulus Therapeutics Recent Developments
- 8.10 ProQR
- 8.10.1 ProQR Company Information
- 8.10.2 ProQR Business Overview
- 8.10.3 ProQR Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.10.4 ProQR Oligonucleotide Therapy-based Drug Product Portfolio
- 8.10.5 ProQR Recent Developments
- 8.11 Nippon Shinyaku
- 8.11.1 Nippon Shinyaku Company Information
- 8.11.2 Nippon Shinyaku Business Overview
- 8.11.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.11.4 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Portfolio
- 8.11.5 Nippon Shinyaku Recent Developments
- 8.12 Moderna Therapeutics
- 8.12.1 Moderna Therapeutics Company Information
- 8.12.2 Moderna Therapeutics Business Overview
- 8.12.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.12.4 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
- 8.12.5 Moderna Therapeutics Recent Developments
- 8.13 MiNA Therapeutics
- 8.13.1 MiNA Therapeutics Company Information
- 8.13.2 MiNA Therapeutics Business Overview
- 8.13.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.13.4 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
- 8.13.5 MiNA Therapeutics Recent Developments
- 8.14 Jazz Pharmaceuticals
- 8.14.1 Jazz Pharmaceuticals Company Information
- 8.14.2 Jazz Pharmaceuticals Business Overview
- 8.14.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.14.4 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
- 8.14.5 Jazz Pharmaceuticals Recent Developments
- 8.15 Ionis Pharmaceuticals
- 8.15.1 Ionis Pharmaceuticals Company Information
- 8.15.2 Ionis Pharmaceuticals Business Overview
- 8.15.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.15.4 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
- 8.15.5 Ionis Pharmaceuticals Recent Developments
- 8.16 Dicerna
- 8.16.1 Dicerna Company Information
- 8.16.2 Dicerna Business Overview
- 8.16.3 Dicerna Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.16.4 Dicerna Oligonucleotide Therapy-based Drug Product Portfolio
- 8.16.5 Dicerna Recent Developments
- 8.17 CureVac
- 8.17.1 CureVac Company Information
- 8.17.2 CureVac Business Overview
- 8.17.3 CureVac Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.17.4 CureVac Oligonucleotide Therapy-based Drug Product Portfolio
- 8.17.5 CureVac Recent Developments
- 8.18 BioNTech
- 8.18.1 BioNTech Company Information
- 8.18.2 BioNTech Business Overview
- 8.18.3 BioNTech Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.18.4 BioNTech Oligonucleotide Therapy-based Drug Product Portfolio
- 8.18.5 BioNTech Recent Developments
- 8.19 Arrowhead
- 8.19.1 Arrowhead Company Information
- 8.19.2 Arrowhead Business Overview
- 8.19.3 Arrowhead Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.19.4 Arrowhead Oligonucleotide Therapy-based Drug Product Portfolio
- 8.19.5 Arrowhead Recent Developments
- 8.20 Alnylam
- 8.20.1 Alnylam Company Information
- 8.20.2 Alnylam Business Overview
- 8.20.3 Alnylam Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
- 8.20.4 Alnylam Oligonucleotide Therapy-based Drug Product Portfolio
- 8.20.5 Alnylam Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst